1. Home
  2. PACB vs ABVX Comparison

PACB vs ABVX Comparison

Compare PACB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACB
  • ABVX
  • Stock Information
  • Founded
  • PACB 2000
  • ABVX 2013
  • Country
  • PACB United States
  • ABVX France
  • Employees
  • PACB N/A
  • ABVX N/A
  • Industry
  • PACB Biotechnology: Laboratory Analytical Instruments
  • ABVX
  • Sector
  • PACB Industrials
  • ABVX
  • Exchange
  • PACB Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • PACB 462.1M
  • ABVX 511.3M
  • IPO Year
  • PACB 2010
  • ABVX N/A
  • Fundamental
  • Price
  • PACB $1.32
  • ABVX $69.10
  • Analyst Decision
  • PACB Buy
  • ABVX Buy
  • Analyst Count
  • PACB 9
  • ABVX 7
  • Target Price
  • PACB $2.06
  • ABVX $74.86
  • AVG Volume (30 Days)
  • PACB 7.4M
  • ABVX 3.2M
  • Earning Date
  • PACB 08-07-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • PACB N/A
  • ABVX N/A
  • EPS Growth
  • PACB N/A
  • ABVX N/A
  • EPS
  • PACB N/A
  • ABVX N/A
  • Revenue
  • PACB $152,357,000.00
  • ABVX $11,444,012.00
  • Revenue This Year
  • PACB $3.36
  • ABVX N/A
  • Revenue Next Year
  • PACB $18.20
  • ABVX $41.36
  • P/E Ratio
  • PACB N/A
  • ABVX N/A
  • Revenue Growth
  • PACB N/A
  • ABVX 128.98
  • 52 Week Low
  • PACB $0.85
  • ABVX $4.77
  • 52 Week High
  • PACB $2.72
  • ABVX $75.51
  • Technical
  • Relative Strength Index (RSI)
  • PACB 47.27
  • ABVX 87.66
  • Support Level
  • PACB $1.25
  • ABVX $67.09
  • Resistance Level
  • PACB $1.44
  • ABVX $72.69
  • Average True Range (ATR)
  • PACB 0.13
  • ABVX 3.94
  • MACD
  • PACB -0.03
  • ABVX 0.67
  • Stochastic Oscillator
  • PACB 21.57
  • ABVX 94.48

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: